Physician Photo

Mohammed Amin (Amin) Arnaout, MD

Physician

Dr. Arnaout is a physician-scientist in the Department of Medicine at Massachusetts General Hospital in Boston. He is Chief-Emeritus of the Division of Nephrology at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School.

  • Phone: 617-726-5050
Departments
Nephrology
Department of Medicine

Specialties

  • Transplant Center
  • Kidney Transplant
  • Vascular Center
  • Nephrology
Clinical Interests
Inflammatory kidney diseases
General nephrology
Polycystic kidney disease
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, American University of Beirut
Residency, Johns Hopkins Hospital
Fellowship, Brigham and Women's Hospital
Fellowship, Children's Hospital Boston
Board Certifications
Nephrology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Gender
Male
Patient Gateway
Yes, learn more
Foreign Languages
Arabic
French
Patient Age Group
Adult
Accepting New Patients
No

BiographyDr. Arnaout received his medical degree with distinction from the American University of Beirut, Lebanon. He served on the medical staff of the American University of Beirut Hospital as an intern and resident in Medicine before moving to Johns Hopkins where he completed his residency. He then moved to Harvard where he finished fellowships in immunology and nephrology at Boston's Childrens Hospital and Brigham and Women's Hospital. Dr. Arnaout is a physician-scientist and served as Chief of the Division of Nephrology at Massachusetts General Hospital from 1998-2013. He currently serves as Director of Leukocyte Biology & Inflammation Program and the Structural Biology Program in the Department of Medicine and Nephrology at Massachusetts General Hospital. 

Research

Our laboratoryis interested in elucidating the molecular basis of human disease and in usingthis information to guide development of new and safer therapies. We utilizestate of the art technologies, including genetics, genomics, biochemistry, cellbiology, structural and computational biology and animal models of disease. Areas of interest include integrinbiology and structure, pathogenesis of autosomal dominant polycystic kidneydisease, lineage commitment in hematopoietic stem cells, mechanisms of ischemic kidney injuryand regeneration and engineering kidney assistdevices.


Publications

View my most recent publications at PubMed

Selected:

  1. Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR.1985. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med. 312:457.
  2. Michishita M, Videm V, Arnaout MA. 1993. A novel divalent cation-binding site in the A- domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell. 72: 857.
  3. Lee JO, Rieu P, Arnaout MA (Corresp. author), Liddington R. 1995. Crystal structure of the A domain of the alpha subunit of integrin CR3 (CD11b/CD18). Cell. 80:631.
  4. Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF. 2000. Polycystin-2, the protein mutated in autosomal dominant Polycystic Kidney Disease (ADPKD), is a Ca2+-permeable non-selective cation channel. Proc. Natl Acad. Sci. USA. 98:1182.
  5. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. 2001. Crystal structure of the extracellular segment of integrin alphaV/beta3. Science. 294:339.
  6. Xiong JP, Stehle T, Zhang R, Dunker R, Joachimiak A, Frech M, Goodman SL, Arnaout MA. 2002. Crystal structure of the extracellular domain of integrin alphaV/beta3 in complex with an Arg-Gly-Asp Ligand. Science. 296:151.
  7. Van Agthoven JF, Xiong JP, Rui X, Alonso JL, Adair BD, Goodman SL, Arnaout MA. 2014. Structural basis for prue antagonism of  alphaV/beta3 by a high affinity form of fibronectin. Nature Struc Mol Biol 21:383.

Mass. General study identifies path to safer drugs for heart disease, cancer

MGH investigators may have found a way to solve a problem that has plagued a group of drugs called ligand-mimicking integrin inhibitors, which have the potential to treat conditions ranging from heart attacks to cancer metastasis.

Renal Associates
165 Cambridge Street
Suite 302
Boston, MA 02114-2752

Phone: 617-726-5050
Phone 2: 617-726-5663
Fax: 617-643-6722